title: In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: yes.
authors.affiliation: Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, USA. foxr@ccf.org
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Fox
mesh_terms: D000284:Administration, Oral; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003437:Crotonates / Q000008:administration & dosage / Q000009:adverse effects; D000069462:Dimethyl Fumarate; D000068876:Fingolimod Hydrochloride; D005650:Fumarates / Q000008:administration & dosage / Q000009:adverse effects; D000068717:Glatiramer Acetate; D006801:Humans; D006885:Hydroxybutyrates; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects*; D007372:Interferons / Q000008:administration & dosage / Q000009:adverse effects*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D009570:Nitriles; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects*; D011409:Propylene Glycols / Q000008:administration & dosage / Q000009:adverse effects; D013110:Sphingosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D014052:Toluidines / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003437:Crotonates; D005650:Fumarates; D006885:Hydroxybutyrates; D007155:Immunologic Factors; D000069442:Natalizumab; D009570:Nitriles; D010455:Peptides; D011409:Propylene Glycols; D014052:Toluidines; C527525:teriflunomide; D000068717:Glatiramer Acetate; D007372:Interferons; D000069462:Dimethyl Fumarate; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine